BPC-157: A Deep Animal Record, A Thin Human File

The short version

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide fifteen amino acids long, copied from part of a protective protein in human gastric juice. In animal studies — overwhelmingly rats — it appears to speed up healing in several tissues: tendons, the gut lining, muscle, and nerve ^[5]. The most consistent explanation researchers give is that it helps grow new blood vessels into an injury, delivering the oxygen and nutrients repair requires ^[4].

Here is the honest part. Almost all of this evidence is in animals. As of 2025 reviews, only three small human pilot studies exist; no large, rigorous human trials have been completed ^[2]. BPC-157 is not an approved drug anywhere, it is banned in sport, and popular claims about weight loss or muscle building are not supported by the published science ^[2]. This page summarizes what was studied; it is not advice and lists no human dose.

What it is

BPC-157 is a stable gastric pentadecapeptide — fifteen amino acids, resistant to breakdown in the stomach — derived from a cytoprotective protein in gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is catalogued under research designations including PL 14736, PLD-116, and PL-10. It is a synthetic research peptide: not a natural extract, and not an approved drug.

How it works

The best-characterized mechanism is angiogenesis — the formation of new blood vessels. In a 2017 study spanning a chick-membrane model, rat hindlimb ischemia, and human vascular endothelial cells, BPC-157 up-regulated VEGFR2 expression and promoted receptor internalization, activating the downstream VEGFR2-Akt-eNOS pathway ^[4]. Blocking that internalization blocked the effect. In plain terms: it appears to make blood-vessel cells more responsive to the body's own vessel-growth signal and accelerated blood-flow recovery in an ischemic muscle model ^[4].

Additional reported pathways include FAK-paxillin cell-migration signaling, growth-hormone-receptor sensitization in tendon fibroblasts, and modulation of brain-gut axis neurotransmitter systems ^[2]. The picture is a peptide that nudges several repair-related signals at once rather than hitting a single target.

What the research shows

Gastric cytoprotection. In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated healing, with intramuscular delivery outperforming intragastric; ulcer-inhibition ratios reached roughly 46-66% at higher doses ^[5].

Pharmacokinetics. First formal PK/ADME work — in rats and beagle dogs — found linear pharmacokinetics, an elimination half-life under 30 minutes, intramuscular bioavailability of approximately 14-19% in rats and 45-51% in dogs, and rapid breakdown into small fragments that re-enter normal amino-acid metabolism ^[3]. The intact peptide does not linger in the bloodstream.

Angiogenesis mechanism. The 2017 study in multiple models demonstrated VEGFR2 up-regulation and internalization as the central pro-angiogenic mechanism, with downstream Akt-eNOS signaling driving vessel growth and blood-flow recovery ^[4].

Human evidence. It is genuinely small. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated, with no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. The sample was two people; this was a safety pilot, not an efficacy trial. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, rigorous large-scale trials are lacking, and the peptide should be treated as investigational ^[2].

Reported effects, cautions & safety

The available safety record within the tiny human dataset and animal work is reassuring as far as it goes — but the absence of long-term, large-sample human data means the actual safety profile is genuinely unknown ^[2].

Cautions from the literature:

• Preclinical-heavy record. Most evidence comes from rodents, and a large share of the foundational work originates from a single research group, which newer authors explicitly flag as an independent-replication concern ^[2].
• Unregulated supply. BPC-157 is not an approved drug and is widely distributed through non-regulated channels, so product identity, purity and dose are unverified outside formal studies.
• Banned in sport. WADA prohibits it at all times under the S0 non-approved-substances category — a direct concern for competitive athletes.
• Unsupported claims. Weight loss, muscle building, and testosterone effects are not supported by the published evidence ^[2].

No community-anecdote reports are compiled in this digest's source material for BPC-157, so none are presented; cautions above are drawn from the cited literature.

Where it fits in recovery research

BPC-157 has the deepest animal record on this digest — but breadth is not the same as depth. Its preclinical evidence spans tendon, gut, muscle and nerve repair, unified by an angiogenesis-forward story, while its human file remains three small pilots ^[2]. Read alongside TB-500, which approaches repair through actin regulation and cell migration, BPC-157 illustrates the central tension of this field: a coherent, decades-long preclinical signal that has barely crossed into controlled human work. See the comparison page for how the two line up.